Yingjie Wang^1,#, Wanlin Dong^1,#, Can Wang², Zirui Li¹, Yongqiang Wang¹, Qi Li¹, Cheng-Ya Dong^1,*

Oncology Research, Vol.33, No.12, pp. 4093-4111, 2025, DOI:10.32604/or.2025.068313 - 27 November 2025

Abstract Objectives: Glioblastoma is a prevalent malignant brain tumor, and the actions of the long non-coding RNA HOXA10-AS in its invasion and migration remain unclear. Here, the function of HOXA10-AS in glioblastoma cell invasion and migration and associated mechanisms were investigated. Methods: HOXA10-AS was knocked down in glioblastoma cells, and Transwell and wound healing assays were conducted to elucidate its impacts on cell invasion and migration. Western blotting and quantitative reverse transcription polymerase chain reaction (qRT-PCR) assessed HOXA10-AS’s impact on the epithelial-mesenchymal transition (EMT). Microarray analysis identified differentially expressed genes, complemented by bioinformatics approaches to explore… More >

Jianing Xu^*†, Qiyu Bo^‡, Xiang Zhang^§, Dapeng Lei^†, Jue Wang^*, Xinliang Pan^†

Oncology Research, Vol.28, No.3, pp. 311-319, 2020, DOI:10.3727/096504020X15801233454611

Abstract Hypopharyngeal squamous cell carcinoma (HSCC) remains one of the most lethal malignancies in the head and neck. Long noncoding RNA (lncRNA) HOXA11-AS is proven to function as an oncogene and a therapeutic target in various tumors. Our previous study and others have demonstrated that HOXA11-AS is one of the most upregulated lncRNAs in HSCC. However, the role of HOXA11-AS in HSCC has not yet been identified. The current study demonstrated that the expression of HOXA11-AS was significantly upregulated in HSCC tumors and was positively associated with lymph node metastasis. Moreover, functional experiments revealed that HOXA11-AS More >

Dongling Zou^*, Qi Zhou^†, Dong Wang^†, Lili Guan^*, Li Yuan^*†, Shaolin Li^*

Oncology Research, Vol.28, No.4, pp. 447-449, 2020, DOI:10.3727/096504020X15970683241756

Abstract It has been demonstrated that microRNAs (miRNAs) act as oncogenes or tumor suppressors in a variety of cancers. Our previous work suggested that miR-10a/b functioned as a tumor suppressor in gastric cancer, and miR-10b was also reported to be significantly downregulated in advanced stage cervical cancer tissues. However, the aberrant expression of miR-10b in cervical cancer and its possible role in cervical carcinogenesis was largely unknown. In this study, we investigated the expression of miR-10b in cervical cancer tissues, carcinoma in situ tissues, mild dysplasia, moderate dysplasia, severe dysplasia tissues, and normal controls. We found More >

Heming Li^*1, Junfeng Li^*1, Taisheng Yang^*, Shuwen Lin^†, Heng Li^‡

Oncology Research, Vol.26, No.2, pp. 315-322, 2018, DOI:10.3727/096504017X15067856789781

Abstract The aberrant expression of miR-433 has been validated in some types of cancers. However, the expression profile and the biological function of miR-433 on colon cancer are still elusive. This study was designed to investigate the function of miR-433 on the proliferation and invasion of colon cancer cells. We detected the expression of miR-433 in colon cancer tissues, adjacent normal tissues, and cell lines. CCK8 and Transwell assays were performed to explore the impact of miR-433 on colon cancer cell proliferation and invasion. The luciferase reporter assay was applied to identify the direct target of More >

Dongling Zou^*, Qi Zhou^†, Dong Wang^†, Lili Guan^*, Li Yuan^*†, Shaolin Li^*

Oncology Research, Vol.24, No.2, pp. 99-108, 2016, DOI:10.3727/096504016X14611963142173

Abstract It has been demonstrated that microRNAs (miRNAs) act as oncogenes or tumor suppressors in a variety of cancers. Our previous work suggested that miR-10a/b functioned as a tumor suppressor in gastric cancer, and miR-10b was also reported to be significantly downregulated in advanced stage cervical cancer tissues. However, the aberrant expression of miR-10b in cervical cancer and its possible role in cervical carcinogenesis was largely unknown. In this study, we investigated the expression of miR-10b in cervical cancer tissues, carcinoma in situ tissues, mild dysplasia, moderate dysplasia, severe dysplasia tissues, and normal controls. We found More >